Impact of Environmental Factors and Metabolomics on Colorectal Cancer.

Dong Peng

Status: Active, not recruiting

Conditions: Metabolic Disease; Colorectal Cancer

Treatments: Diagnostic Test: colorectal neoplasm; Diagnostic Test: colorectal cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06643429

2024-222-02

Details and patient eligibility

About

Colorectal cancer is one of the malignant tumours with high morbidity and mortality worldwide, posing a serious threat to human health. In recent years, the incidence of colorectal cancer has been on the rise with changes in lifestyle and dietary habits. Although some progress has been made in treatments such as surgery, chemotherapy and radiotherapy, however, the early diagnosis, prognosis assessment and personalised treatment of colorectal cancer still face great challenges. Therefore, it is of great academic value and practical significance to deeply explore the influencing factors of colorectal cancer occurrence, development and its prognosis, especially the research on environmental factors and metabolomics.

Full description

In this study, investigators collected clinical information, blood, urine and stool for ambient air pollution analysis, blood metabolomics analysis and stool macro-genetic sequencing by including patients from healthy control and colorectal cancer groups, respectively. Environmental factors, metabolomics and intestinal microbiota data were integrated and analysed to screen for indicators that play a key role in colorectal cancer development and construct a colorectal cancer prediction model.

Enrollment: 700 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy control group:

   • age ≥18 years old;
   • no history of malignant tumour;
   • willing to participate in this study and sign the informed consent form;
   • complete basic data.

2. Gastric cancer group:

   • age ≥18 years old;
   • patients diagnosed with gastric cancer by pathological biopsy before operation;
   • no chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
   • willing to participate in this study and sign the informed consent; complete clinical data.

Exclusion criteria

• patients with primary malignant tumours other than gastric cancer;
• patients with serious cardiopulmonary insufficiency and other systemic diseases that affect the choice of treatment plan;
• patients who are not suitable for enrolment as assessed by the investigator.

Trial design

700 participants in 3 patient groups

the control group

Description:

Adults with no history of malignancy and willing to participate in this study.

the colorectal cancer group

Description:

Patients with preoperative diagnosis of colorectal cancer confirmed by pathological biopsy.

Treatment:

Diagnostic Test: colorectal cancer

the colorectal adenoma group

Description:

Patients with preoperative diagnosis of colorectal adenoma confirmed by colonoscopy.

Treatment:

Diagnostic Test: colorectal neoplasm